Endo Pharmaceuticals Holdings Inc. is getting a new company name: Endo Health Solutions Inc.


Endo Pharmaceuticals Holdings, Endo Health Solutions, new company name, new name, corporate identity, Dave Holveck, AMS, medical devices, branded pharmaceuticals, HealthTronics, medical services, practice management software, laboratory solutions, medical records technology, Qualitest, generic drugs




























































































































































































































INSIDE THIS ISSUE
News
Opinion
Other Services
Reprints / E-Prints
Submit News
White Papers

Supplier News Breaks Archives

Endo Pharmaceuticals adopts new identity

May 23rd, 2012

CHADDS FORD, Pa. – Endo Pharmaceuticals Holdings Inc. is getting a new company name: Endo Health Solutions Inc.

The company said Endo Pharmaceuticals stockholders voted in favor of the name change on Wednesday at the annual shareholders meeting.

Endo noted that the new name comes with the launch of a new corporate identity that more accurately reflects the company's new business model. Endo Health Solutions said it has aggregated four operating businesses into one enterprise aimed at delivering integrated, end-to-end solutions — mainly in pain management and urology — for the benefit of providers, payers and patients.

Under the new corporate architecture, Endo Health Solutions will deliver products and services through four operating segments: AMS, a developer of innovative medical devices; Endo Pharmaceuticals, a provider of branded pharmaceuticals; HealthTronics, a provider of medical services, including practice management software, laboratory solutions and medical records technology; and Qualitest, a manufacturer of generic drugs.

Endo explained that its vision is to approach therapeutic areas and disease states as pathways, and to identify, develop and incorporate medical interventions beyond the traditional chemical and biological treatments.

"This important decision by our shareholders marks a milestone in our company's history," stated Dave Holveck, president and chief executive officer, "and reinforces our position in the market as a leading provider of health solutions, merging health care information and a broader array of innovative treatment options that can ultimately lead to improved health outcomes for patients."

Advertisement